Literature DB >> 18086836

Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality.

Mitchell J Schwaber1, Shiri Klarfeld-Lidji, Shiri Navon-Venezia, David Schwartz, Azita Leavitt, Yehuda Carmeli.   

Abstract

Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an emerging nosocomial pathogen. Little is known about its risk factors or mortality. We performed a case-case-control study to assess the risks for CRKP isolation and a retrospective cohort study to assess mortality in three groups of hospitalized adults: (i) patients from whom CRKP was isolated, (ii) patients from whom carbapenem-susceptible Klebsiella spp. (CSKS) were isolated, and (iii) controls from whom no Klebsiella spp. were isolated. After adjustment for length of stay (LOS), the demographics, comorbidities, and exposures of each case group were compared with those of the controls. Significant covariates were incorporated into LOS-adjusted multivariable models. In the mortality study, we evaluated the effect of CRKP on in-hospital death. There were 48 patients with CRKP isolation (21 died [44%]), 56 patients with CSKS isolation (7 died [12.5%]), and 59 controls (1 died [2%]). Independent risk factors for CRKP isolation were poor functional status (odds ratio [OR], 15.4; 95% confidence interval [CI], 4.0 to 58.6; P < 0.001); intensive care unit (ICU) stay (OR, 17.4; 95% CI, 1.5 to 201.9; P = 0.02); and receipt of antibiotics (OR, 4.4; 95% CI, 1.0 to 19.2; P = 0.05), particularly fluoroquinolones (OR, 7.2; 95% CI, 1.1 to 49.4; P = 0.04). CRKP was independently associated with death when patients with CRKP were compared with patients with CSKS (OR, 5.4; 95% CI, 1.7 to 17.1; P = 0.005) and with controls (OR, 6.7; 95% CI, 2.4 to 18.8; P < 0.001). After adjustment for the severity of illness, CRKP isolation remained predictive of death, albeit with a lower OR (for the CRKP group versus the CSKS group, OR, 3.9; 95% CI, 1.1 to 13.6; and P = 0.03; for the CRKP group versus the controls, OR, 5.0; 95% CI, 1.7 to 14.8; and P = 0.004). CRKP affects patients with poor functional status, an ICU stay, and antibiotic exposure and is an independent predictor of death.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18086836      PMCID: PMC2258527          DOI: 10.1128/AAC.01020-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel.

Authors:  Shiri Navon-Venezia; Inna Chmelnitsky; Azita Leavitt; Mitchell J Schwaber; David Schwartz; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 2.  The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance.

Authors:  Keith S Kaye; Anthony D Harris; Matthew Samore; Yehuda Carmeli
Journal:  Infect Control Hosp Epidemiol       Date:  2005-04       Impact factor: 3.254

3.  Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae.

Authors:  Mitchell J Schwaber; Shiri Navon-Venezia; Keith S Kaye; Ronen Ben-Ami; David Schwartz; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

Authors:  Valerie Aloush; Shiri Navon-Venezia; Yardena Seigman-Igra; Shaltiel Cabili; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  Outbreaks in distinct regions due to a single Klebsiella pneumoniae clone carrying a bla VIM-1 metallo-{beta}-lactamase gene.

Authors:  Alexandros Ikonomidis; Despina Tokatlidou; Ioulia Kristo; Danai Sofianou; Athanassios Tsakris; Paraskevi Mantzana; Spyros Pournaras; Antonios N Maniatis
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 6.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

7.  Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium.

Authors:  Simona Bratu; David Landman; Robin Haag; Rose Recco; Antonella Eramo; Maqsood Alam; John Quale
Journal:  Arch Intern Med       Date:  2005-06-27

8.  Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents.

Authors:  Simona Bratu; Pooja Tolaney; Usha Karumudi; John Quale; Mohamad Mooty; Satyen Nichani; David Landman
Journal:  J Antimicrob Chemother       Date:  2005-05-25       Impact factor: 5.790

9.  Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital.

Authors:  R Ben-Ami; M J Schwaber; S Navon-Venezia; D Schwartz; M Giladi; I Chmelnitsky; A Leavitt; Y Carmeli
Journal:  Clin Infect Dis       Date:  2006-02-27       Impact factor: 9.079

10.  Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel.

Authors:  Zmira Samra; Orit Ofir; Yinon Lishtzinsky; Liora Madar-Shapiro; Jihad Bishara
Journal:  Int J Antimicrob Agents       Date:  2007-10-10       Impact factor: 5.283

View more
  157 in total

1.  The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae.

Authors:  Meredith G Jernigan; Ellen G Press; M Hong Nguyen; Cornelius J Clancy; Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

Review 2.  Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis.

Authors:  Mical Paul; Vered Shani; Eli Muchtar; Galia Kariv; Eyal Robenshtok; Leonard Leibovici
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

3.  Imported Klebsiella pneumoniae carbapenemase-producing K. pneumoniae clones in a Greek hospital: impact of infection control measures for restraining their dissemination.

Authors:  Aggeliki Poulou; Evangelia Voulgari; Georgia Vrioni; Grigorios Xidopoulos; Aris Pliagkos; Vassiliki Chatzipantazi; Fani Markou; Athanassios Tsakris
Journal:  J Clin Microbiol       Date:  2012-05-30       Impact factor: 5.948

4.  Impact of the Timing of Antibiotic Administration on Digestive Colonization with Carbapenemase-Producing Enterobacteriaceae in a Murine Model.

Authors:  Rémi Le Guern; Teddy Grandjean; Marvin Bauduin; Martin Figeac; Guillaume Millot; Aurore Loquet; Karine Faure; Eric Kipnis; Rodrigue Dessein
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

5.  Population Structure of Klebsiella pneumoniae Causing Bloodstream Infections at a New York City Tertiary Care Hospital: Diversification of Multidrug-Resistant Isolates.

Authors:  Angela Gomez-Simmonds; Michelle Greenman; Sean B Sullivan; Joshua P Tanner; Madeleine G Sowash; Susan Whittier; Anne-Catrin Uhlemann
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

Review 6.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

7.  Pediatric carbapenem-resistant Enterobacteriaceae in Los Angeles, California, a high-prevalence region in the United States.

Authors:  Pia S Pannaraj; Jennifer Dien Bard; Chiara Cerini; Scott J Weissman
Journal:  Pediatr Infect Dis J       Date:  2015-01       Impact factor: 2.129

8.  Activity of Ertapenem against Enterobacteriaceae in seven global regions-SMART 2012-2016.

Authors:  Sibylle H Lob; Meredith A Hackel; Daryl J Hoban; Katherine Young; Mary R Motyl; Daniel F Sahm
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-12       Impact factor: 3.267

9.  In Vitro Assessment of Combined Polymyxin B and Minocycline Therapy against Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae.

Authors:  Dennis Huang; Brenda Yu; John K Diep; Rajnikant Sharma; Michael Dudley; Jussimara Monteiro; Keith S Kaye; Jason M Pogue; Cely Saad Abboud; Gauri G Rao
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

10.  A model for predicting nosocomial carbapenem-resistant Klebsiella pneumoniae infection.

Authors:  Duo Yang; Zeqiang Xie; Xuli Xin; Wenying Xue; Man Zhang
Journal:  Biomed Rep       Date:  2016-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.